177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life

Chen, Luohai; Quigley, Ann‐Marie; Gnanasegaran, Gopinath; Mandair, Dalvinder; Toumpanakis, Christos; Caplin, Martyn; Hayes, Aimee R.

doi:10.1007/s00259-021-05332-0

Cited by 7 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other factors such as interim ascites, the presence of ≥5 bone metastases, and NETs other than GEP were predictors of worse OS ( 35 ). The importance of bone metastasis is also confirmed by the evidence that an increase in baseline alkaline phosphatase is associated with poorer PFS and OS ( 25 , 26 ). Das et al.…”

Section: Resultsmentioning

confidence: 84%

“…The most common hematological adverse events were grade 1–2 lymphocytopenia and anemia. An increase in creatinine values after PRRT occurred in 12.7% of patients (grade 1–2) ( 26 ). In a small study evaluating the combination of 177 Lu-DOTATATE and 90 Y-DOTATOC therapy in 9 patients affected by NETs with a large bulky lesion (≥5 cm), posttreatment imaging showed excellent uptake of the radionuclides in the lesions in almost all patients, and only mild-grade adverse events were observed ( 31 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

New Insights in PRRT: Lessons From 2021

et al. 2022

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of 177Lu-Oxodotreotide (DOTATATE) or 90Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possible future increase of PRRT applications, using it in other NETs, as a neoadjuvant treatment, or for rechallenge. Regarding safety, available studies, even those with long follow-up, supported the low rates of adverse events, even though 1.8% of treated patients developed a second malignancy. Finally, there is a lack of prognostic and predictive factors for PRRT, with the exception of the crucial role of nuclear imaging for both patient selection and treatment response estimation.

show abstract

Section: Resultsmentioning

confidence: 84%

Section: Resultsmentioning

confidence: 99%

New Insights in PRRT: Lessons From 2021

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Twelve studies evaluated HRQoL in patients with NEN treated with PRRT (Table 1). Eight of these studies were retrospective analyses [15][16][17][18][19][20][21][22], and four studies were prospective analyses [23][24][25][26]. 177 Lutetium was the radioisotope administered in 11 of the 12 studies, and only in one study patients were treated with 225 Ac-DOTATATE [24].…”

Section: Effect Of Prrt On Hrqolmentioning

confidence: 99%

“…Scores at baseline, before PRRT treatment, were compared with those recorded at the end of treatment (i.e., from 6 weeks to 3 months after the last PRRT cycle). The quantification of the mean changings for each item of the questionnaires was described in eight of the 12 studies, whereas these data were not available in three studies [16,21,25]; in the study by Strosberg et al [23], the authors considered as outcome the time to deterioration, i.e., the time from random assignment to the first deterioration of 10 or more points (on a 100-point scale) compared with baseline score for the same domain. Therefore, to summarize our findings by including all the selected studies we used a graphical method.…”

Section: Effect Of Prrt On Hrqolmentioning

confidence: 99%

“…Relative to the baseline scores, the following items were unchanged after PRRT in all the selected studies: nausea/vomiting, dyspnea, constipation, and economic impact. As shown in Table 3, three studies applied the EORTC QLQ-GINET21 to analyze HRQoL [21,23,24]. In all these studies, the authors found an improvement in the disease-related worries in patients treated with PRRT.…”

Section: Functional Scales Physicalmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms

Malandrino

Mazzilli

Puliani

et al. 2022

Cancers

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT), also called radioligand therapy, is an effective antitumoral treatment in patients with neuroendocrine neoplasm (NEN). It improves the patient’s health-related quality of life (HRQoL), which is evaluated by self-assessment questionnaires. The aim of this narrative review was to report the current knowledge on the changes of HRQoL and sexual function in patients with NEN treated with PRRT. We conducted a literature search of the PubMed, Embase, and APA PsycInfo databases. We selected 15 studies (12 for HRQoL and three for sexual function). After treatment with PRRT, patients with NEN experienced a significant improvement in their global health status, disease-related worries, social and emotional functioning, and cancer-related symptoms such as fatigue and diarrhea. Other symptoms, such as nausea/vomiting, dyspnea, and constipation, as well as the economic impact, were unchanged by radioligand therapy. Data on sexual function were not equally promising; only a few studies investigated this issue by using appropriate questionnaires in patients treated with radioligand therapy. Therefore, additional studies are needed to draw a conclusion about the benefits from PRRT on sexual function.

show abstract